No Photo Available

Last Update

2016-12-28T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Ingmar Hoerr?

Dr. Ingmar Hoerr

Founder and Chief Executive Officer

CureVac GmbH

Direct Phone: +49 **** *******       

Email: i***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

CureVac GmbH

210 Broadway Suite 201

Cambridge, Massachusetts 02139

United States

Company Description

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical company has more than 15 years ... more

Find other employees at this company (107)

Background Information

Employment History

Administrative Coordinator

Wold Architects and Engineers

Behavioral Therapist

Lovaas Institute

Research Assistant and Author

Dr. Cynthia Meyer, Counseling Skills

Server

Keegan's Irish Pub

Counselor

Waukesha Family Ymca

MBA Fellow, Executive Ass. To Chief Executive Officer

EMC microcollections

Affiliations

Advisory Board Member
Europe Unlimited S.A

January 2013-May 2014 Active Member, Secretary 2013-2014 School Year
Family Social Sciences Round Table

Education

MBA

Danube University

MBA

Danube University of Krems

PhD

University of Tübingen

PhD

biology

Tuebingen University

Web References (164 Total References)


Company news - Biotechgate

bionova.biotechgate.com [cached]

TUBINGEN, Germany, Dec. 28, 2016 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced today that Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will present at the J.P. Morgan 35(th) Annual Healthcare Conference 2017... Read more


TUBINGEN, Germany, Dec. 28, 2016 ...

bionova.biotechgate.com [cached]

TUBINGEN, Germany, Dec. 28, 2016 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced today that Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will present at the J.P. Morgan 35(th) Annual Healthcare Conference 2017... Read more


TUBINGEN, Germany, Dec. 28, 2016 ...

bionova.biotechgate.com [cached]

TUBINGEN, Germany, Dec. 28, 2016 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced today that Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will present at the J.P. Morgan 35th Annual Healthcare Conference 2017 to be held January 9-12, 2017, at the Westin St. Francis Hotel in San Francisco, CA.


TUBINGEN, Germany, Dec. 28, 2016 ...

bionova.biotechgate.com [cached]

TUBINGEN, Germany, Dec. 28, 2016 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced today that Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will present at the J.P. Morgan 35th Annual Healthcare Conference 2017 to be held January 9-12, 2017, at the Westin St. Francis Hotel in San Francisco, CA.


curevac.de: Company

www.curevac.com [cached]

In the late 1990s, Dr. Ingmar Hoerr, Co-founder and CEO of CureVac, made an unexpected discovery during his doctoral research in biology, which was contrary to the established scientific belief at the time: RNA, which was generally thought to be a very unstable biomolecule, could be administered directly into tissue as a therapeutic vaccine or agent once the biological properties of the molecule were appropriately modified. Furthermore, complicated formulations or molecular packaging were not required to achieve these results.

This discovery led to a new fundamental understanding of the potential of RNA to treat diseases and to generate prophylactic immunity. These fascinating possibilities prompted the company's three founders, Ingmar Hoerr, Steve Pascolo and Florian von der Mülbe, to found CureVac without investors during the difficult market environment of 2000.

Similar Profiles

Other People with this Name

Other people with the name Hoerr

Robert Hoerr
P.J. Hoerr , Inc.

Frederic Hoerr
Veterinary Diagnostic Pathology LLC

Jesse Hoerr
P.J. Hoerr , Inc.

Cheryl Hoerr

Carle Hoerr
APOSTOLIC CHRISTIAN COUNSELING INC

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory